Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab... see more

TSX:MBX - Post Discussion

Microbix Biosystems Inc. > StatCan just dropped a bombshell...
View:
Post by prophetoffactz on Dec 08, 2023 5:12pm

StatCan just dropped a bombshell...

StatCan just dropped a bombshell report on LC. This is the most important figure. It highlights that the risk of long term symptoms is cumulative, it increases with increasing number of infections. By 3+ infections, 38% report long term symptoms — that’s 1 in every 2.6 people.

Data table for Chart 2  Percentage of Canadian adults with long term symptoms, by number of self reported covid-19 infections, June 2023 1 infection  14.6% 2 infections  25.4% 3 or more infections  37.9%
Comment by prophetoffactz on Dec 08, 2023 5:20pm
Government policy flipped to 'don't test' for COVID... Given the increased cumulative risk of long COVID with each infection they may be forced to reevaluate policy. Widespread repeat infection is going to be costly with each new wave.
Comment by prophetoffactz on Dec 08, 2023 7:30pm
@DavidSteadson   Less than 24hrs after I did this thread, @StatCan_eng published the first report I have seen on prevalence of ever having ...more  
Comment by prophetoffactz on Dec 09, 2023 9:47am
Comment by rjc7 on Dec 10, 2023 9:49am
MBX is NOT a COVID play
Comment by tasman99 on Dec 10, 2023 11:59am
how large of a bomb for mbx? fire cracker -1 london blitz -5 Hiroshima -10
Comment by prophetoffactz on Dec 10, 2023 1:51pm
Sure looks like MBX could be a COVID play once again. If COVID is causing increased long term damage to the human population with each infection and damaging the human immune system creating a paradise for pathogens testing could be a path to help control the situation. Government policy shifted to 'don't test' an tried to normalize infection but the mounting long term costs could ...more  
Comment by prophetoffactz on Dec 10, 2023 4:37pm
Canada's Chief Science Advisor says it's best not to get infected with COVID at all... @ChiefSciCan    ...more  
Comment by prophetoffactz on Dec 10, 2023 4:41pm
The German Health Minister, himself a doctor, warns: “Covid remains dangerous. It's not a cold that you can safely catch every season. Rather, it affects the blood vessels or weakens the immune system, which means it cannot be completely cured.”
Comment by wizzdumb on Dec 10, 2023 7:41pm
More testing definitely a positive for both QAPs and potentitally VTM. Long COVID includes increased risk of clotting which can be treated by Kinlytic. MBX is definitely not a pure COVID play but I it definitely won't hurt if it starts getting more attention again. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities